【摘要】 预防或治疗化疗药物对肿瘤病人肝脏损害的问题，为改善化疗期生活质量的重要内含之一。本文首次报道了７０例（化疗２０２例次）实体瘤化疗期并用肝得健６００ｍｇ／次，３次／日，平均服药３周，与５５例（化疗２３１例次）单用化疗者比较。肝功能损害率各为１６．８％（３４／２０２）和４４．２％（１０２／２３１）（Ｐ＜０．００００１，χ２＝３６．０８８９）。ＷＨＯⅢ／Ⅳ度肝功损害各为２．５％（５／２０２）与１３．９％（３２／２３１），（Ｐ＜０．０００１，χ２＝１６．３８３０）；４周后肝功尚未恢复各为２．９７％（６／２０２）与１７．７４％（４１／２３１）（Ｐ＜０．０００１，χ２＝２２．８２０６）。故本研究结果显示：肝得健在预防化疗药物所致的肝脏损害方面有显著疗效更多还原

【Abstract】 Protection of liver function is important in chemotherapy particularly when drugs which may impair liver functions are used. Seventy patients with solid malignant tumors were treated with chemotherapeutic agents in combination with EPL 600mg tid for 3 weeks (chemotherapy 202 episodes). Fifty five patients were treated with chemotherapy alone (chemotherapy episodes 231) as control. The occurrence of liver function impairment for these two groups were 16.8% (34/202) and 44.2% (102/231) respectively with significant difference ( P <0.00001 χ 2=36.0889). Grade III/IV liver function (WHO) impairment rate were 2.5% (5/202) and 13.9% (32/231) ( P <0.00001 χ 2=16.3830) respectively.更多还原